Download the Article: '21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare'
The 21st Century Cures Act was signed into law last December during the Obama administration. It brings numerous changes to the US drug development landscape, impacting patients, academia, research institutions, and industry. Over the last number of months Blue Latitude have been engaging with US pharma companies to help our clients understand its implications and how it could be leveraged.
Please enter your details so we can email you the content
Our content has moved
We’re posting all new articles on our parent website fishawack.com
Fishawack Health launches Delta Magazine
Our parent company Fishawack Health has launched a new magazine with a first issue unpacking rare disease.
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
SIGN UP TO OUR NEWSLETTER TO RECEIVE
- Our latest articles on industry trends
- Access to downloadable resources
- Updates on pharma events and career opportunities